Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Receivables (2024 - 2026)

Kura Oncology has reported Receivables over the past 3 years, most recently at $9.3 million for Q1 2026.

  • Quarterly Receivables fell 80.82% to $9.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Mar 2026, down 80.82% year-over-year, with the annual reading at $8.8 million for FY2025, 327.38% up from the prior year.
  • Receivables was $9.3 million for Q1 2026 at Kura Oncology, up from $8.8 million in the prior quarter.
  • Over five years, Receivables peaked at $48.7 million in Q1 2025 and troughed at $2.1 million in Q4 2024.
  • The 3-year median for Receivables is $9.1 million (2025), against an average of $18.2 million.
  • Year-over-year, Receivables soared 327.38% in 2025 and then plummeted 80.82% in 2026.
  • A 3-year view of Receivables shows it stood at $2.1 million in 2024, then soared by 327.38% to $8.8 million in 2025, then rose by 6.18% to $9.3 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Receivables are $9.3 million (Q1 2026), $8.8 million (Q4 2025), and $35.9 million (Q3 2025).